Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0851184 (
thinning
)
11,252
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Agrin is a heparan sulfate proteoglycan that is widely expressed in neurons and microvascular basal lamina in the rodent and avian central nervous system. Agrin induces the differentiation of nerve-muscle synapses, but its function in either normal or diseased brains is not known. Alzheimer's disease (AD) is characterized by loss of synapses, changes in microvascular architecture, and formation of neurofibrillary tangles and senile plaques. Here we have asked whether AD causes changes in the distribution and biochemical properties of
agrin
. Immunostaining of normal, aged human central nervous system revealed that
agrin
is expressed in neurons in multiple brain areas. Robust
agrin
immunoreactivity was observed uniformly in the microvascular basal lamina. In AD brains,
agrin
is highly concentrated in both diffuse and neuritic plaques as well as neurofibrillary tangles; neuronal expression of
agrin
also was observed. Furthermore, patients with AD had microvascular alterations characterized by
thinning
and fragmentation of the basal lamina. Detergent extraction and Western blotting showed that virtually all the
agrin
in normal brain is soluble in 1% SDS. In contrast, a large fraction of the
agrin
in AD brains is insoluble under these conditions, suggesting that it is tightly associated with beta-amyloid. Together, these data indicate that the
agrin
abnormalities observed in AD are closely linked to beta-amyloid deposition. These observations suggest that altered
agrin
expression in the microvasculature and the brain parenchyma contribute to the pathogenesis of AD.
...
PMID:Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. 1033 11
APOE4 homozygosity has been associated with an increased risk of sporadic Alzheimer's disease through a mechanism, which has yet to be defined. Recent evidence has suggested that microvascular basement membrane injury may be a critical factor in the pathogenesis of AD-related dementia. In previous studies, we have shown that the synaptic organizing protein
agrin
can be found in neurons, and is a major component of the brain microvascular basement membrane. Here, we compare the basement membrane surface area of cortical microvasculature in AD brains by staining with an anti-
agrin
antibody. Quantitative morphometric analysis was used to determine the mean basement area (micro(2)) of prefrontal cortical microvessels. An average of 10 capillaries was measured in each of 35 cases of AD genotyped for APOE status. APOE4,4 homozygotes had smaller capillary basement membrane areas (17.4 micro(2))+/-6.2) than APOE3,3 homozygotes (26.9 micro(2)+/-6.5), p<0.001. The capillary basement membrane areas (CBMA) of heterozygotes APOE3,4 did not differ significantly from APOE3,3 or APOE4,4. Braak stage did not contribute significantly to CBMA. However, a preliminary analysis suggests an interaction between APOE4,4 and Braak V-VI producing smaller CBMA, a finding which needs to be confirmed with a larger sample. These data support the hypothesis that APOE4,4 is associated with
thinning
of the microvascular basement membrane in Alzheimer's disease.
...
PMID:Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. 1241 81